A Phase 1, Randomized, Placebo-Controlled, Single Ascending Dose-Escalation Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY4167586 in Participants With Obesity or Overweight Who Are Otherwise Healthy
Status: Recruiting
Location: See all (2) locations...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 1
SUMMARY
The purpose of this study is to look at how safe and well-tolerated LY4167586 is in participants with obesity or overweight who are otherwise healthy. Blood tests will be performed to check how much LY4167586 gets into the bloodstream and how long it takes the body to eliminate it following a single administration. Participation in the study will last approximately 7 months.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 65
Healthy Volunteers: t
View:
• Participant must be 21 for Singapore site
• Have a body mass index (BMI) between 27.0 kilogram per square meter (kg/m²) and 35.0 kg/m², inclusive
• Have had a self-reported stable weight for 3 months prior to screening (less than approximately 5 percent \[%\] body weight change)
Locations
United States
Wisconsin
Fortrea Clinical Research Unit
RECRUITING
Madison
Other Locations
Singapore
Lilly Centre for Clinical Pharmacology
RECRUITING
Singapore
Contact Information
Primary
Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or
LillyTrials@Lilly.com
1-317-615-4559
Backup
Physicians interested in becoming principal investigators please contact
clinical_inquiry_hub@lilly.com
Time Frame
Start Date: 2025-11-18
Estimated Completion Date: 2026-12
Participants
Target number of participants: 84
Treatments
Experimental: LY4167586 (Cohorts A1 to A6)
LY4167586 administered subcutaneously (SC)
Placebo_comparator: LY4167586 (Cohorts A1 to A6) Placebo
LY4167586 administered SC
Experimental: LY4167586 (Cohort B)
LY4167586 administered intravenously (IV)
Related Therapeutic Areas
Sponsors
Leads: Eli Lilly and Company